AR061486A1 - Derivados de 2-pirazinacarboxamida - Google Patents

Derivados de 2-pirazinacarboxamida

Info

Publication number
AR061486A1
AR061486A1 ARP070102647A ARP070102647A AR061486A1 AR 061486 A1 AR061486 A1 AR 061486A1 AR P070102647 A ARP070102647 A AR P070102647A AR P070102647 A ARP070102647 A AR P070102647A AR 061486 A1 AR061486 A1 AR 061486A1
Authority
AR
Argentina
Prior art keywords
group
halogen
hydrogen
lower alkyl
cycloalkyl
Prior art date
Application number
ARP070102647A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38616576&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR061486(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR061486A1 publication Critical patent/AR061486A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Estos compuestos son utiles para el tratamiento y/o profilaxis de enfermedades asociadas con la modulacion del receptor de CB1, por ejemplo la obesidad. Reivindicacion 1: Compuestos de la formula general (1) en la que R1 se elige entre el grupo formado por cicloalquilo, que está sin sustituir o sustituido por un grupo elegido entre hidroxi, alcoxi inferior e hidroxialquilo inferior, -CH2-(CR9R10)m-cicloalquilo, dicho cicloalquilo está sin sustituir o sustituido por hidroxi o hidroxialquilo inferior, piperidinilo y -CR11R12-COOR13; m es el numero 0 o 1; R9 se elige entre el grupo formado por hidrogeno, alquilo inferior y cicloalquilo; R10 se elige entre el grupo formado por hidrogeno, hidroxi y alcoxi inferior; R11 y R12 con independencia entre sí son hidrogeno o alquilo inferior; R13 es alquilo inferior; R2 es hidrogeno; R3 es -OR14, en el que R14 se elige entre el grupo formado por alquilo inferior, halogeno-alquilo inferior, cicloalquilo, cicloalquilalquilo inferior, heterociclilalquilo inferior, heteroarilalquilo inferior, alcoxialquilo inferior e hidroxialquilo inferior; o -NR15R16, en el que R15 es hidrogeno o alquilo inferior y R16 se elige entre el grupo formado por alquilo inferior, cicloalquilo, cicloalquilalquilo inferior, hidroxialquilo inferior y alcoxialquilo inferior; o R15 y R16 junto con el átomo de nitrogeno al que están unidos forman un anillo heterocíclico elegido entre el grupo formado por la acetidina, pirrolidina, piperidina y el azepano, dicho anillo heterocíclico está sin sustituir o sustituido por alcoxi; R4 y R8 con independencia entre sí son hidrogeno o halogeno; R5 y R7 con independencia entre sí se eligen entre el grupo formado por hidrogeno, halogeno, halogeno- alquilo inferior, halogeno-alcoxi inferior y ciano; R6 se elige entre el grupo formado por hidrogeno, halogeno, halogeno-alquilo inferior, halogeno-alcoxi inferior y ciano; y las sales farmacéuticamente aceptables de los mismos.
ARP070102647A 2006-06-19 2007-06-15 Derivados de 2-pirazinacarboxamida AR061486A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06115646 2006-06-19

Publications (1)

Publication Number Publication Date
AR061486A1 true AR061486A1 (es) 2008-08-27

Family

ID=38616576

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102647A AR061486A1 (es) 2006-06-19 2007-06-15 Derivados de 2-pirazinacarboxamida

Country Status (20)

Country Link
US (1) US7629346B2 (es)
EP (1) EP2035394B1 (es)
JP (1) JP5139425B2 (es)
KR (1) KR101084451B1 (es)
CN (1) CN101460468B (es)
AR (1) AR061486A1 (es)
AT (1) ATE440090T1 (es)
AU (1) AU2007263150B9 (es)
BR (1) BRPI0713706A2 (es)
CA (1) CA2654781A1 (es)
CL (1) CL2007001778A1 (es)
DE (1) DE602007002070D1 (es)
DK (1) DK2035394T3 (es)
ES (1) ES2329312T3 (es)
IL (1) IL195422A (es)
MX (1) MX2008015933A (es)
PL (1) PL2035394T3 (es)
PT (1) PT2035394E (es)
TW (1) TW200815374A (es)
WO (1) WO2007147746A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7781593B2 (en) * 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
CA2664621A1 (en) * 2006-10-04 2008-04-10 F. Hoffmann-La Roche Ag Pyrazine-2-carboxamide derivatives
RU2454405C2 (ru) * 2006-10-04 2012-06-27 Ф.Хоффманн-Ля Рош Аг Производные 3-пиридинкарбоксамида и 2-пиразинкарбоксамида в качестве агентов, повышающих уровень лвп-холестерина
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2242745A1 (de) * 2008-02-07 2010-10-27 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8088920B2 (en) * 2008-03-31 2012-01-03 Hoffmann-La Roche Inc. 3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as HDL-cholesterol raising agents
US7897621B2 (en) * 2008-03-31 2011-03-01 Hoffmann-La Roche Inc. 2-trifluoromethylnicotinamide derivatives as HDL-cholesterol raising agents
RU2016141566A (ru) 2008-12-19 2018-12-20 Вертекс Фармасьютикалз Инкорпорейтед Производные пиразина, используемые в качестве ингибиторов киназы atr
RU2570416C9 (ru) 2009-12-01 2019-11-25 Эббви Инк. Имидазопирролопиразиновые производные, полезные для лечения заболеваний, вызванных аномальной активностью протеинкиназ Jak1, Jak3 или Syk
US8962631B2 (en) * 2010-05-12 2015-02-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2011143425A2 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
MX2012013081A (es) 2010-05-12 2013-05-09 Vertex Pharma Compuestos utiles como inhibidores de cinasa atr.
WO2012031817A1 (en) 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Determination of abca1 protein levels in cells
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
MX2014001860A (es) * 2011-09-12 2014-05-30 Hoffmann La Roche Hidrazidas del acido 3-piridin carboxilico como agentes elevadores del colesterol de lipoproteina de alta densidad (hdl).
WO2013037721A1 (en) * 2011-09-12 2013-03-21 F. Hoffmann-La Roche Ag 5-cycloalkyl- or 5-heterocyclyl-nicotinamides
BR112014007721B1 (pt) 2011-09-30 2022-11-01 Vertex Pharmaceuticals Incorporated Processos para preparar compostos úteis como inibidores de atr quinase
MX2014003785A (es) 2011-09-30 2014-07-24 Vertex Phamaceuticals Inc Tratamiento del cancer de pancreas y del cancer de pulmon de celulas no pequeñas con inhibidores de atr.
US9403808B2 (en) * 2011-10-28 2016-08-02 Hoffmann-La Roche Inc. Pyrazine derivatives
CA2869309C (en) 2012-04-05 2021-02-09 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase and combination therapies thereof
US8999632B2 (en) 2012-10-04 2015-04-07 Vertex Pharmaceuticals Incorporated Method for measuring ATR inhibition mediated increases in DNA damage
US9512141B2 (en) * 2012-12-07 2016-12-06 Hoffmann-La Roche Inc. Pyrazine derivatives as CB2 receptor agonists
CN103159687A (zh) * 2013-04-12 2013-06-19 苏州科捷生物医药有限公司 一种2-胺基吡嗪-5甲酸的合成方法
CN103467392B (zh) * 2013-10-09 2016-08-17 重庆工商大学 一种多卤代吡嗪甲酰胺衍生物及其盐类、制备方法和用途
AU2016331955B2 (en) 2015-09-30 2022-07-21 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940418A (en) * 1972-04-07 1976-02-24 G. D. Searle & Co. Esters and amides of 4,5-dihydrobenz[g]indazole-3-carboxylic acids and related compounds
FR2713225B1 (fr) 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2714057B1 (fr) 1993-12-17 1996-03-08 Sanofi Elf Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
US5596106A (en) 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
FR2741621B1 (fr) * 1995-11-23 1998-02-13 Sanofi Sa Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
US6100259A (en) 1997-01-21 2000-08-08 Smithkline Beecham Corporation Cannabinoid receptor modulators
WO1998041519A1 (en) 1997-03-18 1998-09-24 Smithkline Beecham Corporation Novel cannabinoid receptor agonists
FR2761265B1 (fr) 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs solvates
FR2761266B1 (fr) 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
FR2783246B1 (fr) 1998-09-11 2000-11-17 Aventis Pharma Sa Derives d'azetidine, leur preparation et les medicaments les contenant
FR2789079B3 (fr) 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
US7393842B2 (en) * 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
FR2800375B1 (fr) 1999-11-03 2004-07-23 Sanofi Synthelabo Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
US6479479B2 (en) * 2000-03-03 2002-11-12 Aventis Pharma S.A. Azetidine derivatives, their preparation and pharmaceutical compositions containing them
FR2805817B1 (fr) 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
US6566356B2 (en) * 2000-03-03 2003-05-20 Aventis Pharma S.A. Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
US6355631B1 (en) * 2000-03-03 2002-03-12 Aventis Pharma S.A. Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
FR2805818B1 (fr) 2000-03-03 2002-04-26 Aventis Pharma Sa Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
FR2805810B1 (fr) 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation
SK287074B6 (sk) 2000-03-23 2009-11-05 Solvay Pharmaceuticals B. V. 4,5-Dihydro-1H-pyrazolové deriváty, spôsoby ich prípravy, medziprodukty a ich použitie
FR2814678B1 (fr) 2000-10-04 2002-12-20 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
US20020091114A1 (en) * 2000-10-04 2002-07-11 Odile Piot-Grosjean Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
US6509367B1 (en) * 2001-09-22 2003-01-21 Virginia Commonwealth University Pyrazole cannabinoid agonist and antagonists
SE0104332D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
SE0104330D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
FR2838438A1 (fr) 2002-04-11 2003-10-17 Sanofi Synthelabo Derives de diphenylpyridine,leur preparation, les compositions pharmaceutiques en contenant
BRPI0410289A (pt) 2003-05-07 2006-05-16 Pfizer Prod Inc ligantes do receptor de canabinóides e suas utilizações
GB0314057D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314049D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
US20040259887A1 (en) 2003-06-18 2004-12-23 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US20060135523A1 (en) 2003-06-18 2006-06-22 Astrazeneca Ab 2-substituted 5,6-diaryl-pyrazine derivatives as cb1 modulator
GB0314261D0 (en) 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents
FR2856684B1 (fr) * 2003-06-26 2008-04-11 Sanofi Synthelabo Derives de diphenylpyridine, leur preparation et leur application en therapeutique
PT1868999E (pt) 2005-04-06 2009-08-06 Hoffmann La Roche Derivados de piridino-3-carboxamida como agonistas inversos de cb1
WO2007011760A2 (en) 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
US7781593B2 (en) * 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
CA2664621A1 (en) * 2006-10-04 2008-04-10 F. Hoffmann-La Roche Ag Pyrazine-2-carboxamide derivatives
US9130571B2 (en) * 2007-07-11 2015-09-08 Kyocera Corporation Initializing a capacitive sensing switch for a wireless device

Also Published As

Publication number Publication date
DK2035394T3 (da) 2009-10-05
KR101084451B1 (ko) 2011-11-21
CN101460468A (zh) 2009-06-17
KR20090026294A (ko) 2009-03-12
DE602007002070D1 (en) 2009-10-01
IL195422A0 (en) 2009-08-03
US20070293509A1 (en) 2007-12-20
AU2007263150B9 (en) 2012-11-01
AU2007263150A1 (en) 2007-12-27
JP2009541247A (ja) 2009-11-26
US7629346B2 (en) 2009-12-08
CN101460468B (zh) 2012-05-30
AU2007263150B2 (en) 2012-05-17
CA2654781A1 (en) 2007-12-27
EP2035394B1 (en) 2009-08-19
PL2035394T3 (pl) 2010-01-29
PT2035394E (pt) 2009-10-13
ES2329312T3 (es) 2009-11-24
IL195422A (en) 2012-06-28
EP2035394A1 (en) 2009-03-18
ATE440090T1 (de) 2009-09-15
CL2007001778A1 (es) 2008-05-23
MX2008015933A (es) 2009-01-13
WO2007147746A1 (en) 2007-12-27
BRPI0713706A2 (pt) 2012-10-30
JP5139425B2 (ja) 2013-02-06
TW200815374A (en) 2008-04-01

Similar Documents

Publication Publication Date Title
AR061486A1 (es) Derivados de 2-pirazinacarboxamida
AR054024A1 (es) Derivados de piridina -3- carboxamida como agonistas inversos de cb1
AR059094A1 (es) Derivados de ciclohexil - sulfonamida
AR049696A1 (es) Derivados de indol
AR057989A1 (es) Derivados de indol-2-il-amida 1,5-sustituida. procesos de obtencion y composiciones farmaceuticas
AR049433A1 (es) Derivados de naftalina
AR060593A1 (es) 5-amido-2-carboxiamida-indoles
CO5690643A2 (es) Derivados de triaza-espiropiperidina para usarlos como inhibidores de glyt-1 en el tratamiento de desordenes neurologicos y neuropsiquiatricos
TNSN07255A1 (en) Cyclohexylamides as dopamine d3, d2 and 5ht 1a antagonists
CO6150164A2 (es) Derivados de 2-metilmorfolina pirido-,pirazo-ypirimido-pirimidina como inhibidores de mtor
AR050281A1 (es) Derivados de indol, indazol e indazolina. procesos de obtencion y composiciones farmaceuticas
AR055878A1 (es) Derivados de ciclopropanocarboxamida
CO5721006A2 (es) Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa
AR056883A1 (es) Derivados de 7-azaindol-2 carboxamida, un proceso para la preparacion de los mismos, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades asociadas con la modulacion de receptores de h3
AR063101A1 (es) Derivados de pirazina-2-carboxiamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento o profilaxis de enfermedades asociadas con la modulacion de receptores del cb2.
PE20090441A1 (es) DERIVADOS DE IMIDAZO[1,2-a]PIRIDIN-2-ILMETIL PIPERIDINA SUSTITUIDA
AR064459A1 (es) Derivados de sulfonamida
AR069796A1 (es) Derivados de bencimidazol, sustituido por carboxilo o por hidroxilo, proceso para prepararlos y composiciones farmaceuticas que los contienen
AR058984A1 (es) Derivados de ciclohexil piperazinil metanona
AR047958A1 (es) Derivados de 1-bencil-5-piperazin-1-il-3,4 dihidro-1h-quinazolin-2-ona y sus derivados 1h-benzo(1,2,6)tiadiazina-2,2-dioxidos y 1,4-dihidro-benzo(d)(1,3)oxazinas-2-ona,como moduladores del receptor 5-ht,para el tratamiento de enfermedades del sistema nervioso central.
PE20100718A1 (es) Derivados triciclicos de 1, 4-dihidropiridina [b, e]-condensados como inhibidores de aurora quinasas
AR057197A1 (es) Derivados de 1, 1-dioxo-tiomorfolinil-indolil-metanona
PE20081152A1 (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3
AR039988A1 (es) Derivados de benzoxazina como moduladores de 5-ht6 y usos de los mismos
AR065180A1 (es) Derivados de indol - 2 - il - piperazin - 1 - il - metanona y composicion farmaceutica

Legal Events

Date Code Title Description
FB Suspension of granting procedure